Abstract
NAD+-dependent DNA ligases (LigA) are essential enzymes found only in bacteria and some virus species. This makes them attractive drug targets. Based on the crystal structure of the NAD+ binding domain of the M. tuberculosis enzyme (MtuLigA) and virtual screening, we have earlier identified several novel classes of inhibitors for this enzyme. These inhibitors bind to the adenylation domain and compete with the cofactor NAD+. Recently, we identified that the BRCT domain is essential for the enzyme activity of MtuLigA. We have used virtual screening to identify compounds from the CAP database that should potentially bind to the BRCT domain. These will now be evaluated as inhibitors of the enzyme with a novel mechanism of action. Challenges faced in designing specific and potent inhibitors of the enzyme which can distinguish between the human adenosine triphosphate (ATP)-dependent ligase and MtuLigA are additionally discussed in this report. Proposed strategies for the design of potent inhibitors with desired properties are also outlined.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
